Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Insmed, Inc.](/topic/$insm)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$insm/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$insm/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XXX% no change  
**1 Month**: XX% +9%  
**6 Months**: XX% -XX%  
**1 Year**: XX% -X%  
**1-Year High**: XXX% on 2025-03-17  
**1-Year Low**: XX% on 2025-10-07  

**Most Supportive Themes**
- **FDA Approval and Positive Data:** (40%) The FDA approval of Brinsupri and positive clinical data are driving positive sentiment.
- **Analyst Upgrades and Price Targets:** (30%) Multiple analysts have raised price targets for Insmed, indicating confidence in the company's future.
- **M&A Potential:** (20%) Goldman Sachs has identified Insmed as a potential M&A target, fueling investor interest.
  
**Most Critical Themes**
- **Market Volatility:** (10%)  General market volatility and sector rotation could impact Insmed's price.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXX      | XX% | XXXXX   | XX% | XX       | X% |
| YouTube | X        | X%  | X       | X%  | X        | X% |
|         |          |     |         |     |          |    |
| Total   | XXX      | XX% | XXXXX   | XX% | XX       | X% |

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Insmed, Inc.

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XXX% no change
1 Month: XX% +9%
6 Months: XX% -XX%
1 Year: XX% -X%
1-Year High: XXX% on 2025-03-17
1-Year Low: XX% on 2025-10-07

Most Supportive Themes

  • FDA Approval and Positive Data: (40%) The FDA approval of Brinsupri and positive clinical data are driving positive sentiment.
  • Analyst Upgrades and Price Targets: (30%) Multiple analysts have raised price targets for Insmed, indicating confidence in the company's future.
  • M&A Potential: (20%) Goldman Sachs has identified Insmed as a potential M&A target, fueling investor interest.

Most Critical Themes

  • Market Volatility: (10%) General market volatility and sector rotation could impact Insmed's price.

Network engagement breakdown:

Network Positive % Neutral % Negative %
X XXX XX% XXXXX XX% XX X%
YouTube X X% X X% X X%
Total XXX XX% XXXXX XX% XX X%
Insmed, Inc. (INSM) Sentiment
/topic/$insm/sentiment